GlassScriptPhysician profile
Bachir Farah
NPI 1336370915
$9,015.77
in general payments reported to CMS, 2019-2025
57 companies · $2,282 in 2025
The $2,282 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $150 · 2021: $72.09 · 2022: $1,220 · 2023: $2,476 · 2024: $2,709 · 2025: $2,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,077 · Education: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,076.86 |
| Education | $390.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,011.21 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $773.51 | 2022-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $647.04 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $571.36 | 2023-2025 | |
| Janssen Biotech, INC. | $510.15 | 2021-2025 | Rybrevant, Tecvayli, Carvykti |
| Astrazeneca Pharmaceuticals LP | $385.80 | 2022-2025 | Lynparza, Calquence, Enhertu |
| Emd Serono, INC. | $362.51 | 2023-2025 | Bavencio |
| Genzyme Corporation | $324.20 | 2022-2025 | |
| Abbvie INC. | $322.36 | 2023-2025 | |
| Amgen INC. | $313.53 | 2019-2023 | Lumakras, Kyprolis, Mvasi |
| Astellas Pharma US INC | $261.86 | 2020-2025 | Xospata, Vyloy, Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $229.87 | 2023-2025 | Fruzaqla, Alunbrig, Iclusig |
| Daiichi Sankyo INC. | $229.05 | 2022-2025 | Enhertu, Datroway |
| Seagen INC. | $217.09 | 2022-2023 | Padcev, Tukysa |
| Celgene Corporation | $185.19 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $181.77 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $179.89 | 2022-2025 | Libtayo |
| Incyte Corporation | $178.03 | 2022-2025 | Jakafi, Pemazyre, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $165.91 | 2023-2025 | |
| Glaxosmithkline, LLC. | $152.68 | 2022-2025 | Ojjaara, Shingrix, Zejula |
| Gilead Sciences, INC. | $141.09 | 2021-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $127.25 | 2022-2023 | Imbruvica, Epkinly |
| Servier Pharmaceuticals LLC | $118.80 | 2023-2025 | |
| Genentech USA, INC. | $116.15 | 2023-2024 | Polivy, Lunsumio, Columvi |
| Exelixis INC. | $109.82 | 2023-2024 | Cabometyx |
| Cardinal Health 108 LLC | $92.93 | 2025 | |
| Alexion Pharmaceuticals, INC. | $68.95 | 2023-2025 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $61.59 | 2022-2024 | Tavalisse, Rezlidhia |
| Jazz Pharmaceuticals INC. | $61.41 | 2023-2024 | |
| Eisai INC. | $58.37 | 2022-2023 | |
| Agios Pharmaceuticals, INC. | $51.31 | 2024-2025 | Pyrukynd |
| Adaptive Biotechnologies Corporation | $50.95 | 2022-2025 | Clonoseq |
| Stemline Therapeutics INC. | $50.75 | 2022-2023 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.60 | 2023-2024 | Gilotrif |
| Ipsen Biopharmaceuticals, INC | $47.85 | 2023-2024 | Tazverik, Onivyde |
| Beigene USA, INC. | $47.03 | 2024 | Brukinsa |
| Kyowa Kirin, INC. | $46.83 | 2024 | Poteligeo |
| Tempus Ai, INC | $41.76 | 2024 | |
| Adc Therapeutics America, INC. | $40.89 | 2023-2025 | |
| Sobi, INC | $40.88 | 2023-2024 | |
| Blueprint Medicines Corporation | $38.79 | 2022-2023 | Ayvakit |
| Syndax Pharmaceuticals, INC. | $37.26 | 2025 | |
| Tersera Therapeutics LLC | $35.92 | 2023 | Xermelo, Zoladex |
| Amneal Pharmaceuticals LLC | $27.48 | 2024 | Avastin |
| Immunocore Limited | $27.42 | 2025 | Kimmtrak |
| Recordati_rare_diseases_inc. | $26.98 | 2025 | Enjaymo |
| Genmab U.S., INC. | $25.90 | 2023 | Tivdak |
| Geron Corporation | $23.00 | 2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $20.05 | 2025 | Monoferric |
| Aveo Pharmaceuticals, INC. | $19.39 | 2024 | |
| Mirati Therapeutics, INC. | $17.83 | 2023 | Krazati |
| Foundation Medicine, INC. | $16.61 | 2023 | |
| Coherus Oncology, INC. | $16.56 | 2022 | |
| Sun Pharmaceutical Industries INC. | $16.13 | 2024 | |
| Emmaus Medical, INC. | $15.39 | 2022 | |
| Pharmaessentia USA Corporation | $12.34 | 2022 | |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bachir Farah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.